CCD provides psychiatric clinical trials in the areas of schizophrenia, bipolar disorder, depression, and Alzheimer’s disease. CCD is recognized in the industry as a high quality researcher and successful enroller for psychiatric trials.
“By adding Comprehensive Clinical Development to the CRA family of trial sites we are able to increase our capabilities to meet the needs of the growing pharmaceutical marketplace,” said Mark S. Hanley, chief executive officer of CRA. “We are excited about this partnership and the opportunity to move into new therapeutic areas of clinical research. CCD has an impressive track record in psychiatric trials, and we see it as an ideal partner as we continue to expand our operations.”